GPCR
$48.59-1.87 (-3.71%)
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate i...
Recent News
Eli Lilly Confirms 'Superior Weight Loss' Of Its Next-Generation Obesity Drug
Eli Lilly reported study results Thursday that confirmed the "superior weight loss profile" of its next-gen obesity drug, retatrutide.
Why Did Eli Lilly Stock Slide 6% Despite Strong GLP-1 Momentum?
LLY stock falls 6% after an HSBC downgrade flagged persisting U.S. pricing pressure, rising market competition and compounded tirzepatide risks, despite strong GLP-1 demand.
Structure Therapeutics Posts 15%+ Weight Loss in ACCESS II for Oral GLP-1 Aleniglipron, Eyes Phase III
Structure Therapeutics (NASDAQ:GPCR) shared new top-line results from its ACCESS II clinical program for aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for chronic weight management. Management also discussed pre-specified interim analyses from the ACCESS open-label exte
Rival GLP-1 pill matches Wegovy weight loss data, adding to competitive pressure on Novo Nordisk
Citi has kept its 'neutral' rating on Novo Nordisk (NYSE:NVO) after a rival company released clinical data showing its oral GLP-1 drug delivered weight loss broadly comparable to Novo's own obesity pill, adding to a growing list of competitive threats facing the Danish pharmaceutical...
These Stocks Are Today’s Movers: Nvidia, Nebius, Meta, Micron, Strategy, Structure Therapeutics, Dollar Tree, and More
Stocks rose Monday as oil prices fell and President Donald Trump called on other countries to join the U.S. in ensuring safe passage through the Strait of Hormuz. Nvidia boss Jensen Huang touted the widespread adoption of Nvidia’s CUDA platform over the past two decades. The memory-chip maker said it plans to build a second manufacturing facility at its site in Taiwan by the end of 2026.